Skin Growths On Dogs: Comprehensive Veterinary Reference Guide

Discovering a new lump, bump, or skin growth on your dog can be alarming. As a pet owner, your immediate concern is whether the growth is cancerous, painful, or requires urgent care. This comprehensive veterinary reference guide provides an exhaustive, evidence-based overview of the most common types of skin growths found in dogs, their causes, diagnostic methods, treatment protocols, and prognostic outcomes.

This guide is designed for veterinary professionals, veterinary students, and dedicated pet owners seeking a deep understanding of canine dermatological neoplasia and benign skin conditions. We will cover everything from common lipomas to aggressive mast cell tumors, including regional variations in disease prevalence across North America, Europe, and Australia.

Quick Q&A: Skin Growths On Dogs

Question: How can I tell if a skin growth on my dog is dangerous? Answer: It is impossible to determine the nature of a skin growth by appearance or feel alone. Any new, changing, or persistent growth should be evaluated by a veterinarian. The only definitive way to diagnose a skin growth is through cytology (fine needle aspirate) or histopathology (biopsy). Dangerous signs include rapid growth, ulceration, bleeding, pain, or a growth that changes color.

Introduction: The Clinical Significance of Skin Growths

Skin growths, also known as cutaneous masses or neoplasms, are among the most common reasons dogs are presented to veterinary clinics. According to the Merck Veterinary Manual, skin tumors are the most frequently diagnosed tumors in dogs, accounting for a significant proportion of all canine neoplasia. The diversity of these growths ranges from benign, harmless lesions to aggressive malignancies that can be life-threatening.

The term "skin growths on dogs" encompasses a broad spectrum of pathologies including benign tumors (lipomas, papillomas, sebaceous adenomas), malignant tumors (mast cell tumors, melanomas, squamous cell carcinomas), cysts (sebaceous cysts, dermoid cysts), and inflammatory lesions (histiocytomas, granulomas). Each type has distinct clinical features, biological behavior, and management requirements.

Anatomy and Pathophysiology of Canine Skin

The skin is the largest organ in the dog's body, serving as a protective barrier against environmental insults, pathogens, and physical trauma. It is composed of three primary layers: the epidermis (outermost), dermis (middle), and hypodermis (subcutaneous layer). Skin growths can arise from any of these layers or from specialized structures within them, such as hair follicles, sebaceous glands, sweat glands, and melanocytes.

The pathogenesis of skin growths involves complex interactions between genetic predisposition, environmental factors, and immune surveillance. While the exact etiology of many growths remains unknown, factors such as chronic inflammation, viral infection (e.g., papillomavirus), ultraviolet radiation exposure, and hormonal influences have been implicated.

Classification of Skin Growths: Benign vs. Malignant

The most critical distinction in evaluating skin growths is determining whether a growth is benign or malignant. This classification profoundly impacts prognosis and treatment decisions.

Benign growths are non-cancerous, slow-growing, well-circumscribed, and do not invade surrounding tissues or metastasize to distant sites. They typically do not cause systemic illness unless they become large enough to interfere with function.

Malignant growths are cancerous, often grow rapidly, are poorly defined, and can invade local tissues and spread to lymph nodes and distant organs. They may cause systemic signs such as weight loss, lethargy, and anorexia.

However, it is crucial to understand that some benign growths can cause significant morbidity due to their location (e.g., a large lipoma on the leg causing lameness), and some malignant growths can be cured with early intervention.

Common Benign Skin Growths in Dogs

Lipomas (Fatty Tumors)

Lipomas are the most common benign mesenchymal tumors in dogs, originating from adipose tissue. They typically present as soft, fluctuant, well-circumscribed masses located in the subcutaneous tissue. They are most commonly found on the trunk, proximal limbs, and neck. Lipomas are generally slow-growing and non-painful. However, a variant known as an infiltrative lipoma can invade underlying muscle and fascia, causing functional impairment.

Diagnosis: Lipomas are often diagnosed via fine needle aspirate (FNA), which yields a greasy, fatty smear with clusters of mature adipocytes. In cases where the mass is deep or has an atypical texture, advanced imaging (ultrasound, CT, or MRI) may be necessary to rule out liposarcoma.

Treatment: Simple lipomas rarely require treatment unless they cause mechanical issues. Surgical excision is curative and straightforward for well-encapsulated lipomas. Infiltrative lipomas require wide surgical margins and may recur.

Sebaceous Gland Tumors

These are among the most common skin tumors in dogs, arising from the sebaceous glands. They include sebaceous adenomas (benign), sebaceous epitheliomas (benign but more proliferative), and sebaceous adenocarcinomas (rarely malignant). They appear as raised, cauliflower-like, often yellowish or pink growths on the head, eyelids, and trunk.

Diagnosis: Cytology shows clusters of well-differentiated sebocytes. Histopathology is required for definitive classification.

Treatment: Surgical removal or cryotherapy is curative for benign forms. Malignant sebaceous adenocarcinoma requires wide excision.

Papillomas (Warts)

Canine papillomas are caused by the canine papillomavirus (CPV). They are most common in young dogs, immunocompromised animals, and dogs in group housing. They present as small, raised, cauliflower-like lesions on the lips, oral cavity, eyelids, and skin. Oral papillomas can cause drooling, halitosis, and difficulty eating.

Diagnosis: Diagnosis is often based on characteristic appearance. Cytology shows koilocytes (cells with perinuclear halos). PCR testing can confirm CPV.

Treatment: Many papillomas regress spontaneously within 1-3 months as the immune system clears the virus. Persistent or problematic lesions can be surgically removed, cryosurgically treated, or treated with immunomodulators (e.g., imiquimod). There is no specific antiviral therapy.

Histiocytomas

Histiocytomas are benign, rapidly proliferating tumors of Langerhans cells (epidermal dendritic cells). They are most common in young dogs (under 3 years of age) and are often found on the head, ears, and limbs. They appear as small, dome-shaped, hairless, button-like growths that are often red and may ulcerate.

Diagnosis: Cytology reveals a uniform population of large, round cells with abundant cytoplasm and round nuclei. Histiocytomas are notorious for spontaneous regression within 2-3 months.

Treatment: Given their self-limiting nature, a "watch and wait" approach is often appropriate. Surgical removal is performed if the lesion is bothersome, infected, or fails to regress.

Sebaceous Cysts (Epidermoid Cysts)

These are not true neoplasms but rather retention cysts of the sebaceous glands. They appear as firm, round, well-circumscribed nodules filled with a cheesy, keratinous material. They are common in breeds like the Chinese Shar-Pei and Boxer.

Diagnosis: FNA yields thick, white, granular material. Cytology shows keratin debris and occasional inflammatory cells.

Treatment: Ruptured or infected cysts may require drainage and antibiotics. Definitive treatment is surgical excision of the entire cyst wall to prevent recurrence.

Common Malignant Skin Growths in Dogs

Mast Cell Tumors (MCTs)

Mast cell tumors are the most common malignant skin tumor in dogs, accounting for 16-21% of all canine skin tumors. They arise from mast cells, which are immune cells involved in allergic reactions. MCTs exhibit highly variable biological behavior, ranging from benign, easily cured lesions to aggressive, metastatic cancers. They are most common in brachycephalic breeds (Boxers, Bulldogs, Pugs, Boston Terriers) and Labrador Retrievers.

Clinical Presentation: MCTs can appear as solitary or multiple nodules, often on the trunk, perineum, and limbs. They may be soft or firm, hairless or ulcerated. A classic but not universal feature is the "Darier's sign" where the tumor becomes red, swollen, and urticated upon manipulation due to mast cell degranulation. This can be a medical emergency as massive degranulation can cause anaphylaxis.

Diagnosis: FNA is highly diagnostic, showing a population of mast cells with characteristic purple-black cytoplasmic granules (metachromatic granules) on Diff-Quik or Wright's stain. Histopathology with grading (Patnaik or Kiupel grading systems) is essential for prognosis. Low-grade (grade I/II) tumors have a good prognosis, while high-grade (grade III or high-grade) tumors have a poor prognosis.

Treatment: Surgical excision with wide margins (2-3 cm laterally and one fascial plane deep) is the standard of care. Margins are evaluated histologically. Incomplete margins or high-grade tumors may require radiation therapy. Systemic chemotherapy (vinblastine, prednisone, lomustine) is used for metastatic disease or unresectable tumors. Tyrosine kinase inhibitors (toceranib, imatinib) are effective for tumors with specific mutations.

Cutaneous Melanoma

Melanomas arise from melanocytes and can be benign (melanocytoma) or malignant (malignant melanoma). Malignant melanoma is a highly aggressive tumor with a strong tendency to metastasize to lymph nodes, lungs, and brain. They are most common in dogs with heavily pigmented skin, such as Schnauzers, Scottish Terriers, and Doberman Pinschers. Oral melanomas are particularly aggressive.

Clinical Presentation: Cutaneous melanomas appear as darkly pigmented (brown to black) nodules, though amelanotic (non-pigmented) variants occur. They are most common on the head, eyelids, digits, and scrotum.

Diagnosis: FNA yields cells with variable amounts of melanin pigment. Histopathology with immunohistochemistry (Melan-A, PNL2, S100) confirms the diagnosis and distinguishes benign from malignant forms.

Treatment: Wide surgical excision is required. Digital melanomas often require amputation of the digit. Radiation therapy is used for incompletely excised tumors. The canine melanoma vaccine (Oncept) is approved for treatment of stage II/III oral melanoma and may be used for cutaneous forms. Prognosis for malignant melanoma is guarded to poor.

Squamous Cell Carcinoma (SCC)

SCC arises from keratinocytes of the epidermis. It is the second most common malignant skin tumor in dogs. Ultraviolet radiation is a significant risk factor, especially in light-skinned, sparsely haired dogs (e.g., Dalmatians, Bull Terriers, white Boxers). SCC can also arise from chronic inflammation (e.g., at sites of burns, scars, or chronic infections).

Clinical Presentation: SCC appears as a raised, ulcerated, crusty, or cauliflower-like mass. It is most common on the head (pinnae, nasal planum, eyelids), digits, and ventral abdomen. SCC of the nail bed often presents as a swollen, painful digit with nail loss.

Diagnosis: FNA is often non-diagnostic due to keratin debris. Biopsy is required. Histopathology shows invasive cords and nests of atypical keratinocytes with keratin pearls.

Treatment: Wide surgical excision is the treatment of choice. For digital SCC, digit amputation is standard. Radiation therapy is effective for incompletely excised or inoperable tumors. Photodynamic therapy and cryotherapy are options for superficial lesions. Prognosis is good for early, well-excised lesions but poor for metastatic disease.

Soft Tissue Sarcomas (STS)

This is a heterogeneous group of malignant mesenchymal tumors arising from connective tissues such as fat (liposarcoma), fibrous tissue (fibrosarcoma), muscle (leiomyosarcoma), and blood vessels (hemangiopericytoma). They are locally invasive and have a moderate metastatic rate.

Clinical Presentation: STS present as firm, often fixed, slow-growing masses in the subcutaneous tissue. They can become very large before detection.

Diagnosis: FNA is often non-diagnostic due to poor cellularity. Core needle biopsy or incisional biopsy is required for diagnosis. Immunohistochemistry is often needed for definitive classification.

Treatment: Wide surgical excision with clean margins is the primary treatment. Radiation therapy is used for marginal excisions. Chemotherapy is reserved for high-grade or metastatic disease.

Less Common and Regional Skin Growths

Hemangioma and Hemangiosarcoma

Hemangiomas are benign vascular tumors; hemangiosarcomas are malignant. Cutaneous hemangiosarcoma is associated with UV exposure and is common in light-skinned dogs. It appears as a red to purple, raised, often ulcerated mass. Visceral hemangiosarcoma (spleen, heart) is more common and aggressive. Treatment is wide surgical excision.

Transmissible Venereal Tumor (TVT)

TVT is a contagious round cell tumor transmitted through direct contact (mating, licking, biting) between dogs. It is most common in free-roaming dogs in tropical and subtropical regions, including parts of the southern United States, Central and South America, and Australia. It appears as a friable, cauliflower-like mass on the external genitalia, but can also affect the oral cavity and nasal passages.

Diagnosis: FNA shows large, round cells with prominent nucleoli.

Treatment: TVT is highly responsive to chemotherapy with vincristine. Surgical excision is rarely needed.

Histiocytic Sarcoma

This aggressive malignancy of histiocytes is most common in Bernese Mountain Dogs, Flat-Coated Retrievers, and Rottweilers. It can present as a localized skin mass or as disseminated disease affecting multiple organs. Treatment involves wide excision and chemotherapy, but prognosis is poor.

Diagnostic Approach to Skin Growths

A systematic diagnostic approach is essential for all skin growths. The following steps are recommended by the AVMA and AAHA guidelines for managing canine skin masses.

Step 1: Signalment and History

Breed, age, and sex are critical. Young dogs are more likely to have histiocytomas or papillomas. Older dogs have a higher incidence of malignant tumors. Brachycephalic breeds are predisposed to MCTs. The duration of the growth, rate of growth, any changes in appearance, and the dog's overall health should be documented.

Step 2: Physical Examination

A complete physical examination is performed, including careful palpation of all lymph nodes. The mass is assessed for:

• Location: Trunk, limbs, head, digits, mucous membranes.
• Size: Measured in three dimensions.
• Consistency: Soft (lipoma), firm (fibroma), hard (osteoma), fluctuant (cyst).
• Mobility: Mobile (benign), fixed to underlying tissues (malignant).
• Surface: Hairless, ulcerated, crusty, pigmented.
• Pain: Painful on palpation (MCT, abscess, neuroma).

Step 3: Fine Needle Aspirate (FNA)

FNA is the first-line diagnostic test for any skin mass. It is minimally invasive, inexpensive, and provides rapid results. A 22-gauge needle is inserted into the mass, and cellular material is aspirated. The sample is expelled onto a glass slide, stained, and examined cytologically.

FNA can differentiate between:

• Lipomas: Mature adipocytes.
• Mast cell tumors: Mast cells with metachromatic granules.
• Histiocytomas: Large round cells.
• Sebaceous cysts: Keratin debris.
• Inflammatory lesions: Neutrophils, macrophages.

FNA has limitations. It cannot always distinguish benign from malignant tumors (e.g., lipoma vs. liposarcoma), and some tumors (e.g., SCC, STS) may yield non-diagnostic samples.

Step 4: Biopsy

A biopsy is required for definitive diagnosis when FNA is non-diagnostic or when malignancy is suspected. There are two types:

• Incisional biopsy: A wedge of tissue is removed for analysis.
• Excisional biopsy: The entire mass is removed for analysis (this is both diagnostic and therapeutic).

Histopathology provides a definitive diagnosis, tumor grade, and assessment of surgical margins.

Step 5: Staging

For confirmed malignant tumors, staging is performed to assess for metastasis. This includes:

• Lymph node aspiration: Regional lymph nodes are sampled.
• Thoracic radiographs (3 views): To detect pulmonary metastases.
• Abdominal ultrasound: For tumors that metastasize to the liver, spleen, or abdominal lymph nodes.
• Advanced imaging (CT, MRI): For complex cases or surgical planning.

Treatment Modalities

Surgical Excision

Surgery is the mainstay of treatment for most skin growths. The goal is complete removal with clean margins. For benign tumors, simple excision is sufficient. For malignant tumors, wide margins (2-3 cm laterally and one fascial plane deep) are required.

Cryotherapy

Cryotherapy uses liquid nitrogen to freeze and destroy small, superficial benign growths such as papillomas, sebaceous adenomas, and small histiocytomas. It is quick, minimally invasive, and does not require sutures.

Laser Surgery

Carbon dioxide laser ablation is effective for superficial lesions and can be used for debulking larger masses. It provides excellent hemostasis.

Radiation Therapy

Radiation is used for incompletely excised malignant tumors (MCT, SCC, STS) or for tumors in locations where wide surgical excision is not possible (e.g., nasal planum, eyelid). It is also used palliatively for painful or bleeding tumors.

Chemotherapy

Chemotherapy is used for systemic disease (metastatic MCT, lymphoma, TVT) or for tumors that are not amenable to surgery or radiation. Common drugs include:

• Vinblastine and prednisone: For MCT.
• Vincristine: For TVT.
• Doxorubicin: For STS and hemangiosarcoma.
• Lomustine (CCNU): For resistant MCT and histiocytic sarcoma.

Targeted Therapy

Tyrosine kinase inhibitors (TKIs) such as toceranib (Palladia) and imatinib (Glivec) target specific mutations in MCTs and other tumors. These drugs are well-tolerated and can induce durable remissions.

Immunotherapy

The canine melanoma vaccine (Oncept) stimulates the immune system to target melanoma cells. It is used for stage II/III oral melanoma and may be beneficial for cutaneous melanoma.

Regional Considerations

North America (US and Canada)

In North America, MCTs are the most common malignant skin tumor, with a high prevalence in Boxers, Bulldogs, and Labrador Retrievers. Tick-borne diseases (e.g., Lyme, ehrlichiosis) can cause skin lesions that mimic neoplasia. The AAHA recommends routine screening for skin masses during annual wellness exams. In Canada, the CVMA emphasizes the importance of early detection in northern breeds predisposed to certain tumors.

Europe

In Europe, the prevalence of MCTs varies by region. UV-associated SCC is more common in southern Europe due to higher sun exposure. The FVE and EMA have strict guidelines for the use of chemotherapeutic agents, particularly in food-producing animals (though this is rarely relevant for companion dogs). European veterinary surgeons often use the Kiupel grading system for MCTs.

Australia

Australia has a high incidence of UV-associated skin cancers (SCC, hemangiosarcoma) due to intense sun exposure. Light-skinned, short-coated breeds are at highest risk. The AVA and DAFF provide guidelines for sun protection in dogs, including the use of pet-safe sunscreens and limiting sun exposure during peak hours. TVT is more common in remote Indigenous communities and among free-roaming dogs.

When to Seek Immediate Veterinary Attention

The following "red flags" warrant urgent veterinary evaluation:

• Rapid growth: A mass that doubles in size within weeks.
• Ulceration or bleeding: A growth that breaks open and bleeds.
• Pain: The dog licks, chews, or guards the area.
• Infection: Purulent discharge, swelling, fever.
• Systemic signs: Lethargy, weight loss, decreased appetite.
• Location: Growths on the eyelids, mouth, anus, or genitals that interfere with function.
• Multiple growths: Sudden appearance of multiple masses.

Prevention and Surveillance

While not all skin growths are preventable, the following measures can reduce risk:

• Sun protection: Limit sun exposure for light-skinned dogs, especially between 10 AM and 4 PM. Apply pet-safe sunscreen to exposed areas (nose, ears, belly).
• Regular skin checks: Monthly head-to-tail examinations at home. Veterinary examinations every 6-12 months.
• Early intervention: Any new growth persisting for more than 2-3 weeks should be evaluated.
• Breed-specific screening: Brachycephalic breeds should have regular screenings for MCTs. Bernese Mountain Dogs and Flat-Coated Retrievers should be monitored for histiocytic sarcoma.

Prognosis

The prognosis for skin growths in dogs is highly variable and depends on:

• Histological type: Benign vs. malignant.
• Tumor grade: Low-grade tumors have a better prognosis.
• Stage: Localized vs. metastatic disease.
• Surgical margins: Complete excision is curative for most localized tumors.
• Location: Tumors in difficult surgical sites (e.g., nasal planum, digits) may have a worse prognosis.

With early detection and appropriate treatment, many dogs with malignant skin tumors can achieve long-term remission or cure.

Frequently Asked Questions

Q: Can I pop a cyst on my dog at home? A: No. Attempting to pop a cyst can cause infection, inflammation, and rupture of the cyst wall, leading to recurrence. Have a veterinarian evaluate and treat cysts.

Q: Are all lumps on older dogs cancerous? A: No. Many lumps in older dogs are benign lipomas or sebaceous adenomas. However, the risk of malignancy increases with age, so all new lumps should be evaluated.

Q: How much does it cost to remove a skin growth from a dog? A: Costs vary widely based on location, size, and complexity. FNA costs $50-$150. Surgical removal ranges from $200-$1,000+ for simple excisions to $1,500-$5,000+ for complex procedures requiring reconstruction.

Q: Can diet prevent skin growths in dogs? A: There is no proven dietary intervention that prevents skin growths. A balanced diet supports overall health and immune function, which may help the body control abnormal cell growth.

Q: Should I be worried if my dog's skin growth is black? A: Black pigmentation can indicate a melanoma, but it can also be seen in benign lesions such as melanocytomas, pigmented papillomas, or old hematomas. Only cytology or biopsy can differentiate.

Conclusion

Skin growths on dogs encompass a wide spectrum of conditions, from harmless fatty lumps to life-threatening cancers. The key to successful management is early detection, accurate diagnosis, and appropriate treatment. Pet owners should perform regular skin checks and seek veterinary evaluation for any new, changing, or concerning growth. Veterinary professionals should adhere to established diagnostic protocols, including FNA and biopsy, and tailor treatment to the individual patient based on tumor type, grade, and stage.

By understanding the diverse nature of skin growths and the principles of their management, we can improve outcomes and quality of life for our canine companions.

References

1. Withrow SJ, Vail DM, Page RL. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier; 2019.
2. Merck Veterinary Manual. Tumors of the Skin and Soft Tissues. 2023. Available at: https://www.merckvetmanual.com
3. American Veterinary Medical Association (AVMA). Canine Skin Masses: A Diagnostic Approach. AVMA Guidelines. 2021.
4. American Animal Hospital Association (AAHA). AAHA Canine Vaccination Guidelines and Wellness Guidelines. 2022.
5. Canadian Veterinary Medical Association (CVMA). Skin Tumors in Dogs: A Review. CVMA Journal. 2020.
6. Australian Veterinary Association (AVA). Skin Cancer in Dogs: Prevention and Management. AVA Clinical Guidelines. 2023.
7. Federation of Veterinarians of Europe (FVE). Guidelines for the Management of Canine Neoplasia. 2021.
8. Cornell College of Veterinary Medicine. Canine Skin Tumors: A Clinical Update. 2022.
9. VCA Animal Hospitals. Skin Lumps and Bumps in Dogs. 2023. Available at: https://vcahospitals.com
10. DVM360. Diagnostic Approach to Canine Skin Masses. 2022. Available at: https://www.dvm360.com
11. Kiupel M, Webster JD, Bailey KL, et al. Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors. Vet Pathol. 2011;48(1):147-155.
12. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol. 1984;21(5):469-474.
13. Thamm DH, Vail DM. Mast cell tumors. In: Withrow SJ, Vail DM, Page RL, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier; 2019:382-403.
14. Bergman PJ. Canine oral melanoma. Clin Tech Small Anim Pract. 2007;22(2):55-60.
15. Lana SE, Ogilvie GK. Hemangiosarcoma. In: Withrow SJ, Vail DM, Page RL, eds. Withrow and MacEwen's Small Animal Clinical Oncology. 6th ed. Elsevier; 2019:679-690.
16. European Medicines Agency (EMA). Guidelines for the Use of Veterinary Medicinal Products in the Treatment of Neoplasia. 2021.
17. EFSA Panel on Animal Health and Welfare. Scientific Opinion on the Welfare of Dogs with Skin Tumors. EFSA Journal. 2020;18(4):6078.
18. Australian Government Department of Agriculture, Fisheries and Forestry (DAFF). Management of Transmissible Venereal Tumor in Dogs. 2022.